The disclosed devices and methods relate generally to implanting prosthetics in a patient, and in particular balloon catheters for delivering and expanding stent-mounted prosthetic heart valves.
Heart valve disease is a serious problem that involves the malfunction of one or more valves of the heart. The malfunction can manifest itself in a variety of manners. For example, valve stenosis is the calcification or narrowing of a native heart valve. As a result, the native heart valve is not able to completely open and blood flow through the native valve is impeded or restricted. Another example of heart valve disease is valve insufficiency. Valve insufficiency is the failure of a native heart valve to close properly to prevent leaking, or backflow, of blood through the valve.
One method of treating valve disease is to replace the native valve with an artificial or prosthetic heart valve. Prosthetic heart valves include stent-mounted soft tissue heart valves that are delivered using a catheter. For example, the prosthetic heart valve may be mounted on the balloon of the balloon catheter. The balloon catheter is advanced to the native heart valve site. Then the balloon is expanded to release or expand the stent supporting the heart valve into place within the native heart valve. The balloon is then deflated and the balloon catheter withdrawn.
Problems have arisen where the stent supporting the tissue valve is expanded in a non-cylindrical manner, for example, when the ends of the stent flare outwards into a dog-bone shape. The flared ends can negatively influence valve performance or can damage the tissue surrounding the implanted valve.
Accordingly, a need exists for improved prosthetic heart valves and/or balloon catheters that deliver them to reduce or eliminate the flared ends of the valves.
Disclosed herein are embodiments of a balloon for expanding a generally cylindrical implant—such as a prosthetic heart valve—wherein the balloon is shaped to have one or more enlarged regions to selectively increase expansion forces on the implant. For example, in one embodiment, the balloon may have a central portion that is enlarged to exert more force on the center of a stent-mounted prosthetic heart valve. This overcomes the stent-mounted prosthetic heart valve's tendency to expand with flared ends. This forms a more cylindrical or barrel shaped stent frame during expansion of the balloon—reducing or eliminating the instance wherein the cylindrical stent frame has flared ends. The flared ends can interfere with implantation or post-implantation function. Alternatively, the balloon may have conical flares placed to cause or enhance flared ends of the cylindrical implant to enhance its anchoring capabilities. In some stent-mounted prosthetic heart valves a flared end will spare wear on the soft-tissue leaflets.
A system is included in one embodiment, the system comprising an implant and a balloon. The implant has a generally cylindrical stent frame with an axial opening. The stent frame has an inflow end defining an inflow diameter, an outflow end defining an outflow diameter and a central region defining a central diameter, the central region being between the inflow end and outflow end. The balloon extends through the axial opening and is configured to expand and exert a radially directed force against the stent frame so that the outflow diameter and inflow diameter are equal to or smaller than the central diameter in an at least partially (e.g., partially or fully) expanded condition. The central diameter of the stent frame can be from 0% to 6% larger than either the inflow or the outflow diameter of the stent frame in the at least partially expanded condition and at a pressure in the balloon of at least 4 atmospheres. The implant could include or be, for example, a prosthetic heart valve.
In one aspect, the inflow diameter of the stent frame in the at least partially expanded condition can be larger than the outflow diameter. Also, the stent frame can have a generally barrel shape such that the central diameter is greater than each of the inflow and outflow diameters.
The balloon, in another aspect, can be configured to exert the radially directed force through 4 to 6 atmospheres of pressure while the outflow and inflow diameters of the stent frame are equal to or smaller than the central diameter.
In another aspect, the central diameter of the stent frame in the partially, or even fully, expanded condition is at most 2 mm larger than either the inflow or the outflow diameter. The central diameter may even be as little as 1.2 mm, or even 0.8 mm, larger than either the inflow or the outflow diameters. The balloon pressure at these central diameters can, in some aspects, be from 4 to 5 atmospheres.
As another example, the central diameter of the stent frame in the at least partially expanded condition is between 0% and 2% larger than the inflow diameter at a pressure in the balloon of at least 4 atmospheres. And, the inflow diameter of the stent frame can be larger than the outflow diameter in the at least partially expanded condition.
In another aspect, the balloon may include enlarged ends. The enlarged ends are configured to extend radially past the outflow end and the inflow end of the stent frame. This may aid in retaining the stent frame on the balloon.
In other aspects, the balloon can have different materials or thicknesses for shaped expansion. For example, the balloon can have wall material with a stiffness adjacent the inflow end and the outflow end of the stent frame that is greater than a stiffness of the wall material at the central region.
In another example, the balloon can be configured to expand to a larger diameter under the central region of the stent frame than under the inflow and outflow ends of the stent frame.
The stent frame can also be configured to have regions of different stiffness. For example, the stent frame can have a lower stiffness at the central region than a stiffness adjacent the inflow and outflow ends. Or, the stent frame can have a lower stiffness adjacent the inflow and outflow ends than a stiffness at the central region.
Also included are methods of inflating the balloon and expanding a cylindrical stent. The method, for example, can include inflating a balloon, positioned in an axial opening of a generally cylindrical stent frame of an implant, to a pressure of at least 4 atmospheres. And, exerting a radial force against the cylindrical stent frame by the inflating the balloon. Then, as a result, expanding the cylindrical stent frame by the exerting the radial force so that an outflow diameter and an inflow diameter of the cylindrical stent frame are equal to or smaller than a central diameter and the central diameter is between 0% and 6% larger than the either the inflow or the outflow diameter. Expanding the generally cylindrical stent frame may include expanding the central diameter so that it is at most 2 mm, or even 1.2 mm, larger than either the inflow or outflow diameters.
The following description of certain examples of a medical apparatus (e.g., a balloon catheter assembly with stent-mounted heart valve) should not be used to limit the scope of the medical apparatus. Other examples, features, aspects, embodiments, and advantages of the medical apparatus will become apparent to those skilled in the art from the following description. As will be realized, the medical apparatus is capable of additional aspects, all without departing from the spirit of the medical apparatus. Accordingly, the drawings and descriptions should be regarded as illustrative in nature and not restrictive.
For purposes of this description, certain aspects, advantages, and novel features of the embodiments of this disclosure are described herein. The described methods, systems, and apparatus should not be construed as limiting in any way. Instead, the present disclosure is directed toward all novel and nonobvious features and aspects of the various disclosed embodiments, alone and in various combinations and sub-combinations with one another. The disclosed methods, systems, and apparatus are not limited to any specific aspect, feature, or combination thereof, nor do the disclosed methods, systems, and apparatus require that any one or more specific advantages be present or problems be solved.
Features, integers, characteristics, compounds, chemical moieties, or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract, and drawings), and/or all of the steps of any method or process so disclosed, can be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The invention is not restricted to the details of any foregoing embodiments. The invention extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract, and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.
It should be appreciated that any patent, publication, or other disclosure material, in whole or in part, that is said to be incorporated by reference herein is incorporated herein only to the extent that the incorporated material does not conflict with existing definitions, statements, or other disclosure material set forth in this disclosure. As such, and to the extent necessary, the disclosure as explicitly set forth herein supersedes any conflicting material incorporated herein by reference. Any material, or portion thereof, that is said to be incorporated by reference herein, but which conflicts with existing definitions, statements, or other disclosure material set forth herein will only be incorporated to the extent that no conflict arises between that incorporated material and the existing disclosure material.
Disclosed herein are balloons for mitigating non-cylindrical or flared expansion of stents, and in particular stent-mounted tissue heart valves. For example, the balloons can be used in procedures for minimally invasive transcatheter heart valve replacement (TAVR), such as the procedures described in U.S. Pat. No. 7,175,656, which is hereby incorporated by reference in its entirety.
In conventional delivery of a balloon-expandable prosthetic heart valve, as shown in prior art
Generally, disclosed herein is a stent mounted heart valve (although embodiments can include just a stent) and balloon and system of using them that can facilitate expansion—even partial expansion—of the stent mounted heart valve in a cylindrical, generally cylindrical, or near-cylindrical (e.g., barrel shaped) configuration. For example, the balloon can include differential expansion characteristics due to thickened material over its ends, allowing the center to expand more freely and form the cylindrical or barrel shape in the stent.
The guide catheter 114 and the balloon catheter 32 illustrated in
The guide catheter 114 includes a handle portion 120 and an elongated guide tube, or shaft, 122 extending from handle portion 120 (
An inflatable balloon 30 is mounted at the distal end of balloon catheter 32. As shown in
Generally, during use, the expandable sheath 1 is passed through the skin of patient (usually over a guidewire) such that the distal end region of the expandable sheath 1 is inserted into a vessel, such as a femoral artery, and then advanced to a wider vessel, such as the abdominal aorta. The delivery apparatus 110 is then inserted into the expandable sheath 1, by first inserting the nose piece 132 through the hemostasis valve at the proximal end of the sheath 1. The steerable guide tube 122 is used to advance the balloon catheter shaft 126 and prosthetic heart valve 24 through to and out of the end of the sheath 1. When the delivery apparatus 110 is at the desired procedure site, the prosthetic heart valve 24 is expanded by balloon inflation to implant the device in the patient's body. If the prosthetic heart valve 24 is positioned proximally to the balloon 30 to reduce the profile of the delivery apparatus 110 (as shown in
The generally cylindrical stent frame 40 extends smoothly and continuously from the outflow end through the central region and to the inflow end. In some embodiments, “generally cylindrical” can encompass a “generally barrel” shape, wherein the central diameter of stent frame 40 is slightly larger than either or both of the inflow or outflow diameters. In any case, the central diameter of the disclosed stent frame 40 is not smaller than the inflow or outflow diameters of the stent frame 40.
The length of the balloon 30 shown in
In the embodiment of
Both of the embodiments shown in
The central portion 50 of the embodiment of
Dimensions of the balloon 30 of
Dimensions of the balloon of
The dimensions of the balloon of
The balloons 30 disclosed herein can be shaped by different approaches alone or in combination. For example, different materials with varying stiffness (less stiff at the central portion 50) might be used to enhance the central portion's 50 diameter. Materials include PET, nylon, PEBAX (polyether block amid) or other polymers with adaptable or selectable ranges of stiffness. In some embodiments, the balloon 30 can have a wall material that is relatively stiff under the inflow and outflow ends 44, 46 of the stent frame 40, and relatively soft under the central region 52 of the stent frame 40. Or, the thickness of the wall of the central portion 50 could be reduced (as shown in
Advantageously, the barrel shaped balloons 30 disclosed herein work well with a skirted prosthetic heart valve 24 because the skirt provides an outer restraint to overexpansion. Modification of the balloon 30 to exert more force at its central portion 50 also increases its potential end diameter. Delivery of other medical implants, such as stents, can also benefit from use of a skirt or other outer covering or restraint to provide an end point to the diameter of the implant's expansion.
The enlarged central portion of the balloon advantageously raises the retention forces of the implant and reduces the chance of migration of the implant. Also, the shaped balloons described herein allow control of the amount of flare in the final expanded shape of the implant. For example, the physician can determine whether to inflate the balloon so as to create a cylindrical shape in the implant or to keep the flare on the ends (or to enhance the flare as disclosed below). Also, the physician can stop inflation of the balloon at a lower diameter than nominal diameter of the implant—protecting from risk of annular rupture. Also, reducing the flare at the ends of the implant reduces chances that the stent frame apices will cause conduction system disturbances and/or tissue perforation at the inflow and outflow ends.
Experiments were run comparing the inflation profile of a conventional balloon and stent mounted prosthetic heart valve against an embodiment of the shaped balloon/valve combinations disclosed herein.
Notably, for the shaped balloon/valve combination of the tested embodiment, the middle diameters at 4, 4.5 and 5 atmospheres were about equal to or exceeded the inflow and outflow diameters.
The actual difference measured between the central diameter M and the outflow diameter O for this tested embodiment was 1.2 mm at 4 atmospheres, 0.8 mm at 4.5 atmospheres, and 0.3 mm at 5 atmospheres (based on the data shown in
The balloons 30 described herein can be used to expand the prosthetic heart valve 24 into cylindrical or barrel shapes for deployment within ranges of pressures. For example, one method of valve implantation includes positioning the balloon 30, with the prosthetic heart valve 24 mounted thereon, within a native heart valve using the delivery apparatus 110. The balloon 30 is inflated to a pressure of at least 4 atmospheres while it is positioned in the native heart valve. Inflating the balloon 30 exerts an outward radial force against the cylindrical stent frame 40 of the prosthetic heart valve 24 so that an outflow diameter and inflow diameter are equal to or smaller than the central (or middle) diameter. For example, the central diameter can be between 0% and 6% larger than the outflow diameter.
The expansion method could also be performed to hit certain tolerances between the central, outflow and inflow diameters. In this manner, then, the method can be used to “tune” the prosthetic heart valve's 24 shape. It should be noted that the balloon designs could be reshaped to be more or less aggressive than the tested embodiment depending upon the desired progression and ranges. In another embodiment, the inflow end 44 may have a diameter smaller than the middle section diameter and the middle section diameter may have a smaller diameter than the outflow end 46 diameter. For example, the diameter of the stent from the inflow end 44 through the middle section and to the outflow end 46 may progressively increase.
In another embodiment, the balloon 30 can be contoured to do the opposite—expand one or both of the inflow and outflow ends 44, 46 of the stent 40 to a larger diameter than the middle section. For example, the balloon 30 can be pre-shaped to give it contours to increase the outward force applied to the inflow and outflow ends 44, 46 of the stent to be more than the outward force applied to the central region 52 of the stent 40.
For this embodiment, without being wed to theory, in certain situations flaring the ends of the stent aids in long-term leaflet durability, as well as sealing and seating of the stent 40 during deployment. In particular, flaring the outflow end 46 of the stent 40 provides additional room for the valve leaflets to open without coming into contact with the stent frame 40—thus improving the effective orifice area (EOA) of the implanted valve.
Flaring of both ends 44, 46 may also press the stent frame 40 up against the annulus which can aid in preventing paravalvular leakage. In addition, flaring the ends 44, 46 can prevent the prosthetic heart valve 24 from migrating under backpressure against the valve. These flared stents need not have the aforementioned disadvantages depending upon positioning of the flares—they can be further out for some applications or closer in for other applications.
These shaped balloons 30 with enlarged ends can also be combined with stents 40 configured to follow the balloon shapes. For example, the stents may also be shaped with enlarged ends in the crimped configuration to facilitate expansion by the balloon into the final, flared shape. The crimped stent may, for example, have a consistent diameter through the central region but pass an inflection point where it begins to flare out into a larger diameter near its ends. Similarly, for barrel-shaped balloon embodiments, the crimped stent may be shaped with tapered ends that have a smaller diameter than the central region. Thus, the central area of the crimped stent will be more likely to expand to a larger diameter than the ends with the enhanced pressure of the central area of the barrel-shaped balloon.
Further, the stents may be provided with selective areas of higher and lower stiffness that correspond with the balloon shapes. For example, the density of stent struts, strut material and/or strut thickness may be adapted to allow easier expansion within selected circumferential bands. For the flared balloon, the ends of the stents may have more struts with a lower thickness, and/or fewer interconnections, enhancing the tendency of the stent to flare at the ends with the additional force supplied by the flared balloon. For the barrel-shaped balloon, the ends of the stents could be provided with thicker, fewer and/or more interconnected struts to reduce the tendency of the inflow and outflow ends to expand along with the reduced inflation pressure being supplied at the ends from the barrel-shaped balloon.
Other useful balloon shapes include the balloon 30 shown in
During application, the shaped balloons can be expanded within stents that have cylindrical shapes when crimped and expand them selectively to have the disclosed features—the flares, waist, belly, etc. Thus the same methods can be applied as described above, but with different areas of enhanced balloon features. The stents 40 can also be selectively weakened at the location of the flares and belly to enhance expansion via the shaped balloons.
Although the disclosure has been shown and described with respect to a certain embodiment or embodiments, it is obvious that equivalent alterations and modifications will occur to others skilled in the art upon the reading and understanding of this specification and the annexed drawings. In particular regard to the various functions performed by the above described elements (components, assemblies, devices, compositions, etc.), the terms (including a reference to a “means”) used to describe such elements are intended to correspond, unless otherwise indicated, to any element which performs the specified function of the described element (i.e., that is functionally equivalent), even though not structurally equivalent to the disclosed structure which performs the function in the herein illustrated exemplary embodiment or embodiments. In addition, while a particular feature of the disclosure may have been described above with respect to only one or more of several illustrated embodiments, such feature may be combined with one or more other features of the other embodiments, as may be desired and advantageous for any given or particular application.
This application is a continuation of U.S. application Ser. No. 16/435,288, filed Jun. 7, 2019, which is a continuation of U.S. application Ser. No. 15/263,204, now U.S. Pat. No. 10,314,703, filed Sep. 12, 2016, issued Jun. 11, 2019 and entitled “Cylindrical Implant and Balloon,” which claims the benefit of U.S. Provisional Application No. 62/221,541, filed Sep. 21, 2015, entitled “Cylindrical Implant and Balloon.” Each of the aforementioned applications is hereby incorporated by reference herein in its entirety and for all purposes.
Number | Name | Date | Kind |
---|---|---|---|
3755823 | Hancock | Sep 1973 | A |
4035849 | Angell et al. | Jul 1977 | A |
4777951 | Cribier et al. | Oct 1988 | A |
4787899 | Lazarus | Nov 1988 | A |
4796629 | Grayzel | Jan 1989 | A |
4856516 | Hillstead | Aug 1989 | A |
4878495 | Grayzel | Nov 1989 | A |
4966604 | Reiss | Oct 1990 | A |
4994077 | Dobben | Feb 1991 | A |
5059177 | Towne et al. | Oct 1991 | A |
5192297 | Hull | Mar 1993 | A |
5282847 | Trescony et al. | Feb 1994 | A |
5370685 | Stevens | Dec 1994 | A |
5411552 | Andersen et al. | May 1995 | A |
5545214 | Stevens | Aug 1996 | A |
5554185 | Block et al. | Sep 1996 | A |
5558644 | Boyd et al. | Sep 1996 | A |
5584803 | Stevens et al. | Dec 1996 | A |
5591195 | Taheri et al. | Jan 1997 | A |
5607464 | Trescony et al. | Mar 1997 | A |
5665115 | Cragg | Sep 1997 | A |
5769812 | Stevens et al. | Jun 1998 | A |
5800508 | Goicoechea et al. | Sep 1998 | A |
5840081 | Andersen et al. | Nov 1998 | A |
5855597 | Jayaraman | Jan 1999 | A |
5925063 | Khosravi | Jul 1999 | A |
6027525 | Suh et al. | Feb 2000 | A |
6168614 | Andersen et al. | Jan 2001 | B1 |
6221091 | Khosravi | Apr 2001 | B1 |
6245102 | Jayaraman | Jun 2001 | B1 |
6302906 | Goicoechea et al. | Oct 2001 | B1 |
6425916 | Garrison et al. | Jul 2002 | B1 |
6454799 | Schreck | Sep 2002 | B1 |
6458153 | Bailey et al. | Oct 2002 | B1 |
6461382 | Cao | Oct 2002 | B1 |
6482228 | Norred | Nov 2002 | B1 |
6527979 | Constantz et al. | Mar 2003 | B2 |
6582462 | Andersen et al. | Jun 2003 | B1 |
6602281 | Klein | Aug 2003 | B1 |
6652578 | Bailey et al. | Nov 2003 | B2 |
6730118 | Spenser et al. | May 2004 | B2 |
6733525 | Yang et al. | May 2004 | B2 |
6764504 | Wang et al. | Jul 2004 | B2 |
6767362 | Schreck | Jul 2004 | B2 |
6830584 | Seguin | Dec 2004 | B1 |
6878162 | Bales et al. | Apr 2005 | B2 |
6893460 | Spenser et al. | May 2005 | B2 |
6908481 | Cribier | Jun 2005 | B2 |
7018406 | Seguin et al. | Mar 2006 | B2 |
7018408 | Bailey et al. | Mar 2006 | B2 |
7276078 | Spenser et al. | Oct 2007 | B2 |
7276084 | Yang et al. | Oct 2007 | B2 |
7318278 | Zhang et al. | Jan 2008 | B2 |
7374571 | Pease et al. | May 2008 | B2 |
7393360 | Spenser et al. | Jul 2008 | B2 |
7462191 | Spenser et al. | Dec 2008 | B2 |
7510575 | Spenser et al. | Mar 2009 | B2 |
7585321 | Cribier | Sep 2009 | B2 |
7618446 | Andersen et al. | Nov 2009 | B2 |
7655034 | Mitchell et al. | Feb 2010 | B2 |
7785366 | Maurer et al. | Aug 2010 | B2 |
7959672 | Salahieh et al. | Jun 2011 | B2 |
7993394 | Hariton et al. | Aug 2011 | B2 |
8029556 | Rowe | Oct 2011 | B2 |
8167932 | Bourang et al. | May 2012 | B2 |
8449606 | Eliasen et al. | May 2013 | B2 |
8652203 | Quadri et al. | Feb 2014 | B2 |
20020026094 | Roth | Feb 2002 | A1 |
20020032481 | Gabbay | Mar 2002 | A1 |
20020138135 | Duerig et al. | Sep 2002 | A1 |
20030050694 | Yang et al. | Mar 2003 | A1 |
20030100939 | Yodfat et al. | May 2003 | A1 |
20030158597 | Quiachon et al. | Aug 2003 | A1 |
20030212454 | Scott et al. | Nov 2003 | A1 |
20040186563 | Lobbi | Sep 2004 | A1 |
20040186565 | Schreck | Sep 2004 | A1 |
20040260389 | Case et al. | Dec 2004 | A1 |
20050075728 | Nguyen et al. | Apr 2005 | A1 |
20050096736 | Osse et al. | May 2005 | A1 |
20050188525 | Weber et al. | Sep 2005 | A1 |
20050203614 | Forster et al. | Sep 2005 | A1 |
20050203617 | Forster et al. | Sep 2005 | A1 |
20050234546 | Nugent et al. | Oct 2005 | A1 |
20060025857 | Bergheim et al. | Feb 2006 | A1 |
20060058872 | Salahieh et al. | Mar 2006 | A1 |
20060149350 | Patel et al. | Jul 2006 | A1 |
20060183383 | Asmus et al. | Aug 2006 | A1 |
20070005131 | Taylor | Jan 2007 | A1 |
20070010876 | Salahieh et al. | Jan 2007 | A1 |
20070010877 | Salahieh et al. | Jan 2007 | A1 |
20070112422 | Dehdashtian | May 2007 | A1 |
20070162102 | Ryan et al. | Jul 2007 | A1 |
20070203503 | Salahieh et al. | Aug 2007 | A1 |
20070203575 | Forster et al. | Aug 2007 | A1 |
20070213813 | Von Segesser et al. | Sep 2007 | A1 |
20070265700 | Eliasen et al. | Nov 2007 | A1 |
20080021546 | Patz | Jan 2008 | A1 |
20080114442 | Mitchell et al. | May 2008 | A1 |
20080125853 | Bailey et al. | May 2008 | A1 |
20080275540 | Wen | Nov 2008 | A1 |
20090157175 | Benichou | Jun 2009 | A1 |
20090276040 | Rowe et al. | Nov 2009 | A1 |
20090281619 | Le et al. | Nov 2009 | A1 |
20090319037 | Rowe et al. | Dec 2009 | A1 |
20100049313 | Alon et al. | Feb 2010 | A1 |
20100168844 | Toomes et al. | Jul 2010 | A1 |
20100198347 | Zakay et al. | Aug 2010 | A1 |
20110015729 | Jimenez et al. | Jan 2011 | A1 |
20110144742 | Madrid | Jun 2011 | A1 |
20120123529 | Levi et al. | May 2012 | A1 |
20120259409 | Nguyen et al. | Oct 2012 | A1 |
20130023985 | Khairkhahan et al. | Jan 2013 | A1 |
20130190857 | Mitra et al. | Jul 2013 | A1 |
20130274873 | Delaloye et al. | Oct 2013 | A1 |
20130317598 | Rowe et al. | Nov 2013 | A1 |
20130331929 | Mitra et al. | Dec 2013 | A1 |
20140194981 | Menk et al. | Jul 2014 | A1 |
20140200661 | Pintor et al. | Jul 2014 | A1 |
20140277417 | Schraut et al. | Sep 2014 | A1 |
20140277419 | Garde et al. | Sep 2014 | A1 |
20140277424 | Oslund | Sep 2014 | A1 |
20140330372 | Weston et al. | Nov 2014 | A1 |
20140343671 | Yohanan et al. | Nov 2014 | A1 |
20140350667 | Braido et al. | Nov 2014 | A1 |
20150073545 | Braido | Mar 2015 | A1 |
20150073546 | Braido | Mar 2015 | A1 |
Number | Date | Country |
---|---|---|
19532846 | Mar 1997 | DE |
19546692 | Jun 1997 | DE |
19857887 | Jul 2000 | DE |
19907646 | Aug 2000 | DE |
0103546 | Mar 1984 | EP |
0597967 | May 1994 | EP |
0592410 | Oct 1995 | EP |
0850607 | Jul 1998 | EP |
1796597 | Jun 2007 | EP |
2788217 | Jul 2000 | FR |
2815844 | May 2002 | FR |
1271508 | Nov 1986 | SU |
9117720 | Nov 1991 | WO |
9301768 | Feb 1993 | WO |
9829057 | Jul 1998 | WO |
9940964 | Aug 1999 | WO |
9947075 | Sep 1999 | WO |
0041652 | Jul 2000 | WO |
0047139 | Aug 2000 | WO |
0149213 | Jul 2001 | WO |
0154625 | Aug 2001 | WO |
0162189 | Aug 2001 | WO |
0164137 | Sep 2001 | WO |
0176510 | Oct 2001 | WO |
0222054 | Mar 2002 | WO |
0236048 | May 2002 | WO |
0247575 | Jun 2002 | WO |
03047468 | Jun 2003 | WO |
2005020855 | Mar 2005 | WO |
2005034812 | Apr 2005 | WO |
2005084595 | Sep 2005 | WO |
2006036156 | Apr 2006 | WO |
2006111391 | Oct 2006 | WO |
2006127089 | Nov 2006 | WO |
2006130194 | Dec 2006 | WO |
2006138173 | Dec 2006 | WO |
2005102015 | Apr 2007 | WO |
2007047488 | Apr 2007 | WO |
2007067942 | Jun 2007 | WO |
2007097983 | Aug 2007 | WO |
2008005405 | Jan 2008 | WO |
2008015257 | Feb 2008 | WO |
2008091515 | Jul 2008 | WO |
2009033469 | Mar 2009 | WO |
2010121076 | Oct 2010 | WO |
Entry |
---|
H.R. Andersen, et al. “Transluminal Implantation of Artificial Heart Valve. Description of a New Expandable Aortic Valve and Initial Results with implantation by Catheter Technique in Closed Chest Pig,” European Heart Journal, No. 13. pp. 704-708. 1992. |
H.R. Andersen “History of Percutaneous Aortic Valve Prosthesis,” Herz No. 34. pp. 343-346. 2009. |
Pavcnik, et al. “Development and initial Experimental Evaluation of a Prosthetic Aortic Valve for Transcatheter Placement,” Cardiovascular Radiology, vol. 183, No. 1. pp 151-154. 1992. |
Bailey, S. “Percutaneous Expandable Prosthetic Valves,” Textbook of Interventional Cardiology vol. 2, 2nd Ed. pp. 1268-1276. 1994. |
Al-Khaja, et al. “Eleven Years' Experience with Carpentier-Edwards Biological Valves in Relation to Survival and Complications,” European Journal of Cardiothoracic Surgery, vol. 3. pp 305-311. 1989. |
Ross, “Aortic Valve Surgery,” At a meeting of the Council on Aug. 4, 1966. pp. 192-197. |
Sabbah, et al. “Mechanical Factors in the Degeneration of Porcine Bioprosthetic Valves: An Overview,” Journal of Cardiac Surgery, vol. 4, No. 4. pp. 302-309. 1989. |
Wheatley, “Valve Prostheses,” Operative Surgery, 4th ed. pp. 415-424. 1986. |
Uchida, “Modifications of Gianturco Expandable Wire Stents,” American Journal of Roentgenology, vol. 150. pp. 1185-1187. 1986. |
Number | Date | Country | |
---|---|---|---|
20220273428 A1 | Sep 2022 | US |
Number | Date | Country | |
---|---|---|---|
62221541 | Sep 2015 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16435288 | Jun 2019 | US |
Child | 17694398 | US | |
Parent | 15263204 | Sep 2016 | US |
Child | 16435288 | US |